Candel Therapeutics, Inc. Investigation - CADL

Company
Candel Therapeutics, Inc. (NASDAQ: CADL)

Learn more about the Candel Therapeutics, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Candel Therapeutics, Inc. Investigation Details

Candel Therapeutics, Inc. shares fell roughly 26% on November 13, 2026, following the Company's disclosure that it now expects to submit its Biologics License Application (BLA) for aglatimagene in localized prostate cancer in mid-2027, instead of the previously indicated fourth quarter of 2026. Management attributed the delay to timelines associated with certain assay refinement and ongoing dialogue with the FDA. On the same day, the Company reported a quarterly net loss of $21.9 million, a nine-month net loss of $69.6 million, and announced a new $50 million at-the-market equity program. This updated timeline contrasted with earlier statements. On August 13, 2026, the Company indicated in its quarterly Form 8-K filing that critical activities were progressing to enable the anticipated BLA submission in Q4 2026. The investigation concerns whether Candel Therapeutics, Inc. adequately disclosed risks related to assay refinement timelines and FDA dialogue ahead of November 12, 2026.

Get Started